Clinical Trials Logo

Hepatocarcinoma clinical trials

View clinical trials related to Hepatocarcinoma.

Filter by:

NCT ID: NCT03382327 Completed - Hepatocarcinoma Clinical Trials

Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas

3D-HAPPI
Start date: October 16, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to assess the benefit of 3D models in the planning of hepatic resection by comparing the changes in the surgical plan based on the analysis of conventional preoperative images (CT-scan and MRI), compared to the surgical plan based on the analysis of 3D reconstruction.

NCT ID: NCT03356236 Recruiting - Hepatocarcinoma Clinical Trials

Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation

Start date: April 17, 2018
Phase:
Study type: Observational

To evaluate the efficacy and safety of Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma following Local Ablation

NCT ID: NCT02519075 Completed - Hepatocarcinoma Clinical Trials

11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE

Start date: April 2015
Phase:
Study type: Observational

Prospective exploratory study specifically investigating the diagnostic and predictive role of 11C-Choline PET/CT and DWI MRI for response assessment in patients affected by HCC and candidate to TARE. A minimum number of 20 patients will be considered for the analysis.

NCT ID: NCT01411579 Completed - Liver Metastases Clinical Trials

Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma

Start date: February 2011
Phase: N/A
Study type: Observational

One of the most recent and interesting field of diagnostic imaging is diffusion-weighted MR imaging (DW-MRI). Various studies evaluated the application of DW-MRI to diffuse liver disease and focal liver lesions providing controversial results, probably due to the difficult reproducibility of the apparent diffusion coefficient (ADC) measurements. It is conceivable that a wide inter/intra-individual variability actually exists in the apparent diffusion coefficient (ADC)-values, and that each apparent diffusion coefficient (ADC)-value presents an higher reliability in measuring the temporal changes of water diffusion within the same individual (longitudinal-evaluation), than in characterizing tissues between different patients (transverse-evaluation). For these reasons, some previous studies assessed the application of DW-MRI in predicting the chemotherapy (CHT) outcome in liver metastases. The rationale of these studies was the overt biochemical changes shown by the neoplastic cells after CHT and the sensitivity of DW-MRI in the identification of such changes. The same authors noticed that the metastatic lesions with the lowest ADC-values present also the best outcome after CHT. Moreover, these studies suggest that it could be possible to assess if each single patient will respond (R) or not (NR) to the CHT through liver DW-MRI performed from 3 days to 3 weeks after the beginning of CHT.